Nephrology

Renoprotective Strategies in IgAN

Advertisement

Conference Reporter® Podcast: Drugs in the IgA Nephropathy Late-Stage Pipeline

conference reporter by Ladan Zand, MD
Overview

The therapeutic pipeline for IgA nephropathy is rapidly expanding, with agents targeting upstream immune drivers and complement pathways. In this podcast discussion, Ladan Zand, MD, comments on key late-stage findings presented at Kidney Week 2026 and considers how APRIL/BAFF-directed and anti-CD38 therapies may fit into clinical practice.

 

Following these presentations, featured expert Ladan Zand, MD, was interviewed by Conference Reporter Associate Editor-in-Chief Rick Davis, MS, RPh. Clinical perspectives from Dr Zand on these findings are presented here.

 

References

Barratt J, Brenner RM, Barbour S, et al. The ORIGIN 3 trial: atacicept in IgA nephropathy [abstract TH-OR109] [session: Opening plenary: ASN president’s medal, ASN president’s address, state-of-the-art lecture, featured high-impact clinical trials]. Abstract presented at: Kidney Week 2026; October 21-25; Denver, CO.

 

Floege J. Clinical rationale, emerging data, and clinical context for CD38-directed therapy in the evolving landscape of IgAN therapies [session: Educational symposium: anti-CD38 therapies for IgAN: is durable remission possible?]. Session presented at: Kidney Week 2026; October 21-25; Denver, CO.

 

Kooienga L, Lee EY, Moradi H, Eliasson Vinterberg JSJ, Lin C, Barratt J. Zigakibart results in sustained proteinuria reduction and remission through 124 weeks of treatment in patients with IgAN [abstract FR-OR064] [session: New IgAN therapies: subgroups, outcomes, and biomarkers]. Abstract presented at: Kidney Week 2026; October 21-25; Denver, CO.

 

Lv J, Liu L, Tang S, et al. Telitacicept for IgA nephropathy: final two-year results of the phase 3 TELIGAN trial [abstract TH-OR111] [session: Opening plenary: ASN president’s medal, ASN president’s address, state-of-the-art lecture, featured high-impact clinical trials]. Abstract presented at: Kidney Week 2026; October 21-25; Denver, CO.

 

Mansour N, Elbarody RMF, Kamel AM. Efficacy and safety of BAFF/APRIL-pathway inhibitors versus placebo in adults with IgA nephropathy: a systematic review with pairwise and network meta-analysis. BMC Nephrol. 2026;27(1):470. doi:10.1186/s12882-026-05267-4

 

Perkovic V, Trimarchi H, Tesar V, et al; VISIONARY Trial Investigators Group. Sibeprenlimab in IgA nephropathy—interim analysis of a phase 3 trial. N Engl J Med. 2026;394(7):635-646. doi:10.1056/NEJMoa2512133

 

Rizk DV, Barratt J, Suzuki Y, et al. Sibeprenlimab in IgA nephropathy: 24 months of data from the phase 3 VISIONARY trial [abstract TH-OR110] [session: Opening plenary: ASN president’s medal, ASN president’s address, state-of-the-art lecture, featured high-impact clinical trials]. Abstract presented at: Kidney Week 2026; October 21-25; Denver, CO.

 

This information is brought to you by Engage Health Media and is not sponsored, endorsed, or accredited by the American Society of Nephrology.

Ladan Zand, MD

Associate Professor of Medicine
Division of Nephrology and Hypertension
Program Director
Glomerular Diseases Fellowship
Mayo Clinic
Rochester, MN

Advertisement